Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-11-01

Clinical Trial Update: NOA-12: BIBF1120 and R-RT in Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating BIBF1120 (nintedanib) with radiotherapy for glioblastoma multiforme has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BIBF1120 (nintedanib)

Snippet

Sponsor: Prof. Dr. Wolfgang Wick | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: TERMINATED